Drug Type Small molecule drug |
Synonyms Birch bark extract, Oleogel-S10, AP-101 + [3] |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (14 Jan 2016), |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Epidermolysis Bullosa Dystrophica | European Union | 21 Jun 2022 | |
Epidermolysis Bullosa Dystrophica | Iceland | 21 Jun 2022 | |
Epidermolysis Bullosa Dystrophica | Liechtenstein | 21 Jun 2022 | |
Epidermolysis Bullosa Dystrophica | Norway | 21 Jun 2022 | |
Epidermolysis Bullosa, Junctional | European Union | 21 Jun 2022 | |
Epidermolysis Bullosa, Junctional | Iceland | 21 Jun 2022 | |
Epidermolysis Bullosa, Junctional | Liechtenstein | 21 Jun 2022 | |
Epidermolysis Bullosa, Junctional | Norway | 21 Jun 2022 | |
Wounds and Injuries | European Union | 14 Jan 2016 | |
Wounds and Injuries | Iceland | 14 Jan 2016 | |
Wounds and Injuries | Liechtenstein | 14 Jan 2016 | |
Wounds and Injuries | Norway | 14 Jan 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epidermolysis Bullosa | NDA/BLA | United States | 28 Feb 2022 | |
Bullous Dystrophy, Hereditary Macular Type | Phase 3 | United States | 29 Mar 2017 | |
Bullous Dystrophy, Hereditary Macular Type | Phase 3 | Argentina | 29 Mar 2017 | |
Bullous Dystrophy, Hereditary Macular Type | Phase 3 | Australia | 29 Mar 2017 | |
Bullous Dystrophy, Hereditary Macular Type | Phase 3 | Austria | 29 Mar 2017 | |
Bullous Dystrophy, Hereditary Macular Type | Phase 3 | Brazil | 29 Mar 2017 | |
Bullous Dystrophy, Hereditary Macular Type | Phase 3 | Chile | 29 Mar 2017 | |
Bullous Dystrophy, Hereditary Macular Type | Phase 3 | Colombia | 29 Mar 2017 | |
Bullous Dystrophy, Hereditary Macular Type | Phase 3 | Czechia | 29 Mar 2017 | |
Bullous Dystrophy, Hereditary Macular Type | Phase 3 | Denmark | 29 Mar 2017 |
NCT03068780 (EASE, FDA) Manual | Phase 3 | 223 | (DDEB) | jhrwvkjkrz(ysgwkbznjx) = pdiadvzkvb zifkwtkcqv (xohcpfxbfl ) | Positive | 18 Dec 2023 | |
Placebo Gel (DDEB) | jhrwvkjkrz(ysgwkbznjx) = lstuzatxig zifkwtkcqv (xohcpfxbfl ) | ||||||
Not Applicable | 205 | nqmfuppxbk(umazqtzewr) = zqjseybxsr vfwppujyfn (vowjzvmona ) | - | 07 Jul 2023 | |||
Control gel | nqmfuppxbk(umazqtzewr) = rfqwlelqbd vfwppujyfn (vowjzvmona ) | ||||||
Phase 3 | 223 | yplkcevgjm(fptsboydov) = ohbfsfkeft gfccyuhdys (zlydocctmx ) View more | Positive | 07 Jul 2022 | |||
Vehicle | yplkcevgjm(fptsboydov) = vebbobwwyk gfccyuhdys (zlydocctmx ) View more | ||||||
Phase 3 | 219 | standard of care+topical betulin gel | rbzpbbmqmw(asrinctvpd): difference = -2.1 (95% CI, -2.7 to -1.5]), P-Value = <0.0001 View more | Positive | 01 Sep 2017 | ||
standard of care | |||||||
Phase 3 | 61 | Octenilin+Oleogel-S10 (Entire Study Population) | vnvqrepewp = pqqpexpcvi dnuxmqlstd (efmownghwd, gfjprfhczh - kuslwcxbpm) | - | 28 Sep 2015 | ||
Octenilin+Oleogel-S10 (Entire Study Population - Systemic AEs) | nbippdfmwp(syrdwbzcdj) = oqxwgzofmo vuxomjecea (kxktuskerq, lfwgypsvdd - jfiumifhru) View more |